A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic
hepatitis B who are either treatment-naive, or who have failed lamivudine- or
interferon-treatment in the past. All patients will receive PEGASYS, 180 micrograms s.c.
weekly for 48 weeks, followed by 48 weeks of treatment-free follow-up. The anticipated time
on study treatment is 3-12 months, and the target sample size is 100-500 individuals.